Deadline Reminder: Faruqi & Faruqi, LLP Investigating Claims
Investors who have experienced losses exceeding $50,000 in Metagenomi between February 9, 2024, and September 26, 2024, are being encouraged to reach out to Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson. The law firm is investigating potential claims against Metagenomi, Inc. (NASDAQ: MGX) and is reminding investors of the upcoming deadline on November 25, 2024, to seek the role of lead plaintiff in a federal securities class action that has been filed against the company.
Faruqi & Faruqi is a well-known national securities law firm with a proven track record of recovering hundreds of millions of dollars for investors since its establishment in 1995. The firm is currently investigating allegations that the Company and its executives violated federal securities laws by making false and/or misleading statements about its collaboration agreement with Moderna.
Metagenomi, a genetic medicines company, went public on February 13, 2024, only to announce less than three months later that it had terminated its collaboration agreement with Moderna. This unexpected news caused a decline in Metagenomi’s stock price, leading to questions about the future of the company’s development.
As the investigation continues, Faruqi & Faruqi, LLP is urging anyone with information regarding Metagenomi’s conduct to come forward, including whistleblowers, former employees, shareholders, and others. To learn more about the class action against Metagenomi or to discuss your legal rights, you can contact Faruqi & Faruqi partner Josh Wilson directly. Stay updated by following Faruqi & Faruqi on LinkedIn and Facebook.
It’s essential to be informed about your options as an investor, especially in situations like this. Remember, you have the right to seek legal recourse and potentially become the lead plaintiff in the class action lawsuit. Don’t hesitate to reach out to Faruqi & Faruqi for more information or to discuss your specific case confidentially.
